000650 仁和药业
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)2.1986.2977.9229.66910.418
总资产报酬率 ROA (%)1.7925.1686.4577.5247.900
投入资产回报率 ROIC (%)2.1496.1617.7689.2729.899

边际利润分析
销售毛利率 (%)36.70436.96437.94037.12236.617
营业利润率 (%)21.52218.81019.01917.85818.498
息税前利润/营业总收入 (%)21.46318.81318.75617.36718.056
净利润/营业总收入 (%)15.78313.79013.90412.50813.808

收益指标分析
经营活动净收益/利润总额(%)97.25293.61992.002109.81599.102
价值变动净收益/利润总额(%)1.26516.32511.4558.4657.176
营业外收支净额/利润总额(%)-0.052-0.047-0.0470.0250.029

偿债能力分析
流动比率 (X)6.5766.4827.5746.1033.934
速动比率 (X)6.0805.7866.8095.5093.541
资产负债率 (%)10.38410.3859.04110.61415.888
带息债务/全部投入资本 (%)1.3631.9211.1071.5135.261
股东权益/带息债务 (%)7,191.6445,073.5128,878.1076,466.0671,785.763
股东权益/负债合计 (%)783.609786.240912.619758.439473.282
利息保障倍数 (X)-450.4931,693.466-74.116-35.063-40.342

营运能力分析
应收账款周转天数 (天)28.67629.13033.92926.85026.590
存货周转天数 (天)57.94082.20266.44651.44558.365